156 results on '"Pietzner K"'
Search Results
2. THE IMPACT OF UROLOGICAL COMPLICATIONS DURING SURGICAL TREATMENT FOR ADVANCED OVARIAN CANCER: EP817
3. Physicians’ attitudes towards use of digital media in clinic and practice: a national NOGGO-AIO intergroup survey
4. Prospektive Erhebung der perioperativen Nüchternheit an 641 Patientinnen – eine multizentrische Zwischenanalyse der Jungen Akademie Gynäkologische Onkologie (JAGO) der NOGGO e.V.
5. SCOUT-1: prospektive nicht-interventionelle Studie in BRCA/HRD-getesteten Patientinnen mit neu-diagnostiziertem Ovarialkarzinom (OC), die geeignet sind für eine Platin-basierte Chemotherapie
6. 1524P Epidemiology and demography of gynecological sarcoma: Results of the prospective intergroup registry for gynecological sarcoma REGSA (NOGGO RU1)
7. Management of malignant dysgerminoma of the ovary
8. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma
9. Welche Bedeutung hat die Qualität der Operation auf die Prognose beim Ovarialkarzinom?
10. Möglichkeiten und Grenzen der Diagnostik beim Ovarialkarzinom
11. Adjuvante Therapiekonzepte beim Ovarialkarzinom: Was ist State of the Art, was ist experimentell?
12. Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
13. 627 SCOUT-1: prospective non-interventional study in BRCA/HRD tested ovarian cancer patients eligible for first-line platinum-based chemotherapy
14. 684 How to breaking bad news: an international survey among physicians and medical students in 1146 participants
15. 278 Real-life data on gynecological sarcoma – therapeutic strategies for primary treatment – results of the german sarcoma registry REGSA (NOGGO RU1)
16. 469 Survey on the usage of PARP-inhibitor therapy in Germany – a national NOGGO/JAGO-AGO intergroup study
17. 764P Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study
18. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature
19. Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer
20. Kinderwunsch und Krebs – mit großen Schritten in die Zukunft: Übersichtsartikel zum Symposium der DGRM im Dezember 2009 in Berlin
21. Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube
22. Qualitätssicherung in der assistierten Reproduktion auf der Grundlage einer qualifizierten Beratung
23. 439 Primary symptoms in women with different histopathological subtypes of gynaecological sarcoma – results of a prospective intergroup registry for gynaecological sarcoma (REGSA – NOGGO RU1)
24. Immune effector cells from ovarian cancer patients undergoing standard chemotherapy can be activated by catumaxomab for efficient killing of epithelial tumor cells: V755
25. Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma (EC) or atypical complex hyperplasia (ACH) in young women with hysteroscopic resection and high-dose progesterone therapy
26. Optimierung des Therapiemanagements gynäkologischer Malignome durch interdisziplinäre und intersektorale Online-Tumorkonferenzen - Ein Projekt der integrierten Versorgung und Versorgungsforschung: PO015
27. Patientinnen mit gynäkologischem Sarkom: Charakteristika aus der Online-Tumorkonferenz für seltene Tumoren
28. Fallbericht eines dedifferenzierten Liposarkoms mit den klinischen Zeichen eines Ovarialkarzinoms sowie eine Zusammenfassung der Literatur
29. Angiosarkom des weiblichen Genitaltraktes – Fallserie eines äußerst seltenen, aggressiven und vielgesichtigen Tumors mit systematischem Review
30. Peritoneal metastasiertes High-grade-Stromasarkom – Eine Kasuistik
31. Patientinnen mit Keimstrang-Stroma-Tumor: Charakteristika aus der Online-Tumorkonferenz für seltene Tumoren
32. Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology : A NOGGO-AGO* survey of 144 Gynecological Departments in Germany
33. Retrospective study of long-term epithelial ovarian cancer survivors: clinical data and population-based cancer registry data
34. User Perceptions and Public Attitudes towards Hydrogen Fuel Cell Fleet Vehicles in the EU
35. Lessons for Low-Power Fuel Cell Vehicles from a Demonstration Project: Results of Techno-Economic, Safety, Environmental and Social Assessment of the EUHYCHAIN MINI-TRANS Project
36. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: Results of the randomised phase IIIb CASIMAS study
37. Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma
38. A rare case of ovarian cancer in pregnancy complicated by pulmonary embolus and myocardial infarction: management dilemmas
39. Quaternary Cytoreductive Surgery in Ovarian Cancer
40. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
41. Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type (OSCCHT)
42. The Prescription of the Morning-After Pill in a Berlin Emergency Department Over a Four-Year Period – User Profiles and Reasons for Use
43. Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer
44. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
45. 8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment
46. First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.
47. Effect of catumaxomab on EpCAM+ tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy.
48. Are there any molecular biologic factors which explain the poorer prognosis of elderly patients with advanced ovarian cancer?
49. Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS).
50. 8029 The expression of CASA in ascites correlates with the overall survival and clinical outcome in patients with ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.